GENETIC VARIANTS & OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN WITH EARLY STAGE BREAST CANCER

2.50
Hdl Handle:
http://hdl.handle.net/10755/164718
Category:
Abstract
Type:
Presentation
Title:
GENETIC VARIANTS & OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN WITH EARLY STAGE BREAST CANCER
Author(s):
Kelly, Patricia
Author Details:
Patricia Kelly, RN MS AOCN, Clinical Education Specialist, Texas Health Resources, Dallas, Texas, USA, email: PatriciaKelly@TexasHealth.org
Abstract:
Bone health and risk for osteoporosis are significant survivorship issues for postmenopausal women with breast cancer. Breast cancer treatments specifically aromatase inhibitor (A.I.) medications accelerate bone loss by reducing circulating levels of estrogen. Aromatase inhibitor induced hypoestrogenemia increases the potential for osteoporosis in a postmenopausal population already at risk based upon age. Women with breast cancer may be at increased risk for osteoporosis based upon their diagnosis alone, a phenomenon that may be related to genetic factors common to both diseases. The vitamin D receptor (VDR) and the estrogen receptor alpha (Era) genes are well-studied genes associated with bone growth in the general population; however, these genes have not been studied in the breast cancer population. Bone mineral density (BMD) is held to be the gold standard for evaluating osteoporosis risk. In general population studies, BMD variations have been shown to be associated with polymorphisms in the VDR and ERa genes. The purpose of this pilot study is to identify genetic factors and associated modifiers that relate to bone mineral density (BMD) in postmenopausal women with a diagnosis of early stage breast cancer (ONS Talking Points, Late Treatment Effects and Survivorship). Aims:(1) Measure BMD and identify associated modifiers in the postmenopausal breast cancer population.(2) Describe polymorphisms for the estrogen receptor gene, Era, and the vitamin D receptor gene, VDR, in the postmenopausal breast cancer population.(3) Determine whether there are differences in BMD and associated modifiers over 3 years among study subsets. Genomics is the conceptual framework, gene-gene and gene-environment interactions and the relationship of genes to health and disease. This longitudinal comparative descriptive study will involve three groups (N=45) of postmenopausal women. At study enrollment, women will have genotyping for polymorphisms in the VDR and Era genes. Participants will have a BMD at baseline and yearly for two years. Descriptive statistics and repeated measures of variance will be used for data analysis. Genetic pathways may help explain osteoporosis variability in postmenopausal women with early stage breast cancer. Baseline evidence is needed to establish osteoporosis screening, prevention, and treatment guidelines in this population.
Repository Posting Date:
27-Oct-2011
Date of Publication:
27-Oct-2011
Conference Date:
2007
Conference Name:
32nd Annual Oncology Nursing Society Congress
Conference Host:
Oncology Nursing Society
Conference Location:
Las Vegas, Nevada, USA
Note:
This is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.

Full metadata record

DC FieldValue Language
dc.type.categoryAbstracten_US
dc.typePresentationen_GB
dc.titleGENETIC VARIANTS & OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN WITH EARLY STAGE BREAST CANCERen_GB
dc.contributor.authorKelly, Patriciaen_US
dc.author.detailsPatricia Kelly, RN MS AOCN, Clinical Education Specialist, Texas Health Resources, Dallas, Texas, USA, email: PatriciaKelly@TexasHealth.orgen_US
dc.identifier.urihttp://hdl.handle.net/10755/164718-
dc.description.abstractBone health and risk for osteoporosis are significant survivorship issues for postmenopausal women with breast cancer. Breast cancer treatments specifically aromatase inhibitor (A.I.) medications accelerate bone loss by reducing circulating levels of estrogen. Aromatase inhibitor induced hypoestrogenemia increases the potential for osteoporosis in a postmenopausal population already at risk based upon age. Women with breast cancer may be at increased risk for osteoporosis based upon their diagnosis alone, a phenomenon that may be related to genetic factors common to both diseases. The vitamin D receptor (VDR) and the estrogen receptor alpha (Era) genes are well-studied genes associated with bone growth in the general population; however, these genes have not been studied in the breast cancer population. Bone mineral density (BMD) is held to be the gold standard for evaluating osteoporosis risk. In general population studies, BMD variations have been shown to be associated with polymorphisms in the VDR and ERa genes. The purpose of this pilot study is to identify genetic factors and associated modifiers that relate to bone mineral density (BMD) in postmenopausal women with a diagnosis of early stage breast cancer (ONS Talking Points, Late Treatment Effects and Survivorship). Aims:(1) Measure BMD and identify associated modifiers in the postmenopausal breast cancer population.(2) Describe polymorphisms for the estrogen receptor gene, Era, and the vitamin D receptor gene, VDR, in the postmenopausal breast cancer population.(3) Determine whether there are differences in BMD and associated modifiers over 3 years among study subsets. Genomics is the conceptual framework, gene-gene and gene-environment interactions and the relationship of genes to health and disease. This longitudinal comparative descriptive study will involve three groups (N=45) of postmenopausal women. At study enrollment, women will have genotyping for polymorphisms in the VDR and Era genes. Participants will have a BMD at baseline and yearly for two years. Descriptive statistics and repeated measures of variance will be used for data analysis. Genetic pathways may help explain osteoporosis variability in postmenopausal women with early stage breast cancer. Baseline evidence is needed to establish osteoporosis screening, prevention, and treatment guidelines in this population.en_GB
dc.date.available2011-10-27T12:05:43Z-
dc.date.issued2011-10-27en_GB
dc.date.accessioned2011-10-27T12:05:43Z-
dc.conference.date2007en_US
dc.conference.name32nd Annual Oncology Nursing Society Congressen_US
dc.conference.hostOncology Nursing Societyen_US
dc.conference.locationLas Vegas, Nevada, USAen_US
dc.description.noteThis is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.-
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.